Gyros Protein Technologies Appoints Mark Vossenaar As Vice President, European Sales

Uppsala, Sweden, 4th May 2017: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, announced today the appointment of Mark Vossenaar as Vice President Sales, Europe, effective immediately.

Mr Vossenaar brings more than 25 years of experience in developing and leading life and health science commercial teams, having worked for large and small companies such as Amersham Bioscience, GE Healthcare, Stratagene, Agilent Technologies and most recently Hill-Rom International.

“We are delighted to welcome Mark to the team.” said Dan Calvo, CEO of Gyros Protein Technologies. “His proven leadership abilities and track record of implementing sales and operations strategies will help us continue to drive growth in the European market.”

Mark Vossenaar commented: “I am excited to join Gyros Protein Technologies and look forward to working with Dan and my new colleagues to achieve the company’s financial and strategic objectives”.

Established in March 2016 by the merger of Gyros AB and Protein Technologies, Inc., Gyros Protein Technologies combines Gyros’ microfluidics, systems development and immunoassay expertise with Protein Technologies’ deep knowledge in developing and manufacturing instruments for peptide synthesis. The Company provides customers an unrivaled range of peptide synthesis and bioanalytical tools for biotherapeutics discovery, development and bioprocessing.

Media contact:
Lorna Cuddon
Zyme Communications
Tel: +44(0)7811996942

About Gyros Protein Technologies (For more information please click here)

Gyros Protein Technologies, enables peptide synthesis and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications. Our low to mid-scale peptide synthesizer platforms are the Tribute®, Prelude® X, Symphony® X, and Sonata®. These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab™xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide synthesis and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics.

Back to news